IORT-photon boost plus hypofractionated whole breast irradiation in patients with breast cancer after primary systemic treatment: feasibility, safety and clinical results von Burgos-Burgos, J, Vega, V, Macias-Verde, D, Vicente, E, Murias, C, Santana, C, Lara, P C

Volltext

79: Real-world use of checkpoint inhibitors in the management of thoracic malignancies: a single-institution experience von Lynch, J, Murias, C, Newsom-Davis, T

Volltext

Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA) von Uccello, M, Moschetta, M, Mak, G, Alam, T, Henriquez, C Murias, Arkenau, H-T

Volltext

Hypofractionated whole breast irradiation after IORT treatment is safe in patients receiving adjuvant chemotherapy von Burgos-Burgos, J., Vega, V., Macias-Verde, D., Gómez, V., Travieso-Aja, M., Travieso, J., Vicente, E., Murias, C., Santana, C., Ospina, J., Lara, P. C.

Volltext

A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresect... von Paplomata, E., Bachelot, T., Mueller, V., Murias, C., Murthy, R.K., Okines, A.F.C., Wardley, A.M., Walker, L.N., Antunes De Melo e Oliveira, A.M.

Volltext

Circulating tumour DNA experience in patients with cancer of unknown primary von Winter, H., Faull, I., Bains, P., Murias, C., Kushnir, M., Forster, M.D., Kulkarni, A., Moore, D., Swanton, C., Shiu, K., Arkenau, H.-T.

Volltext

Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC) von Kushnir, M., Winter, H., Murias, C., Bains, P., Abbosh, C.Z., Papadatos-Pastos, D., Newsome-Davis, T., Ahmed, T., Swanton, C., Forster, M.D., Moore, D., Bennett, P., Faull, I., Lanman, R.B., Arkenau, H.-T.

Volltext

Long-range multicore optical fiber displacement sensor von Alonso-Murias, Monserrat C, Monzón-Hernández, David, Rodríguez-Quiroz, Osvaldo, Antonio-Lopez, J Enrique, Schülzgen, Axel, Amezcua-Correa, Rodrigo, Villatoro, Joel

Volltext

Graphene oxide biohybrid layer enhances sensitivity and anticorrosive properties in refractive index sensor von Alonso-Murias, Monserrat del C, Monzón-Hernández, David, Gravagnuolo, Alfredo Maria, Márquez, Salomón, Giardina, Paola, Morales-Narváez, Eden

Volltext

1476P NUTRitional Index for immune-checkpoint inhibitors (ICI) (NUTRICI) for patients (pts) with metastatic gastro-oesophageal junction (GOJ)/gastric cancer (GC) von Morelli, C., Formica, V., Patrikidou, A., Murias, C., Butt, S-U-R., Lucchetti, J., Renzi, N., Nitti, D., Shiu, K-K., Roselli, M., Arkenau, T.

Volltext

198TiPA randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ un... von Paplomata, E, Bachelot, T, Mueller, V, Murias, C, Murthy, R K, Okines, A F C, Wardley, A M, Walker, L N, Antunes De Melo e Oliveira, A M

Volltext

278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients von Krastev, B., Rai, R., Bulat, I., Maglakelidze, M., Murias, C., Arkenau, H-T., Baird, R.D., Wardley, A.M., Roylance, R., Crijanovschi, A., Gogiladze, M., Tao, W., Beelen, A.P., Sorrentino, J.A.

Volltext

334P Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection von Bulat, I., Maglakelidze, M., Krastev, B., Arkenau, H-T., Murias, C., Baird, R.D., Roylance, R., Wardley, A.M., Crijanovschi, A., Gogiladze, M., Lu, Y., McCullough, A., Jain, S., Wolfgang, C.D., Malik, R., Beelen, A.P.

Volltext

Abstract P6-18-31: PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072 von Adams, S, Hamilton, E, Ott, PA, Cho, D, Kalinsky, K, LoRusso, P, Will, M, Huels, V, Benson, B, Murias, C, Arkenau, H-T

Volltext

152PCirculating tumour DNA experience in patients with cancer of unknown primary von Winter, H, Faull, I, Bains, P, Murias, C, Kushnir, M, Forster, M D, Kulkarni, A, Moore, D, Swanton, C, Shiu, K, Arkenau, H-T

Volltext

1430PCell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC) von Kushnir, M, Winter, H, Murias, C, Bains, P, Abbosh, C Z, Papadatos-Pastos, D, Newsome-Davis, T, Ahmed, T, Swanton, C, Forster, M D, Moore, D, Bennett, P, Faull, I, Lanman, R B, Arkenau, H-T

Volltext

Abstract OT2-07-07: ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT0... von Telli, ML, Lord, S, Dean, E, Abramson, V, Arkenau, H-T, Murias, C, Becerra, C, Tang, R, Penney, MS, Pollard, J, Conboy, G, Fields, SZ, Shapiro, G, Tolaney, SM

Volltext

246. An alternative for inverse solution analysis: A new statistical methodology von Suárez-Murias Pella, C, Quiñónez González, I, Bobes León, M.A, Galán Garcı´a, L

Volltext

3201 Survival analysis of follicular lymphoma in a national registry from the spanish oncology lymphoma group von Codina, J. Gömez, Pèrez, F. Franco, de Juan, V. Calvo, Pulla, M. Provencio, Sabin, P, Mora, M.A. Cruz, Blanco, C. Quero, Bujanda, D. Aguiar, Lavernia, J, Rodriguez-Abreu, D, Llanos, M, Guma, J, De la cruz Merino, L, Lopez-Gonzalez, A, Arroyo, F.R. Garcia, Martinez, N, Sanchez, J.J, Enriquez, C. Murias, Rueda, A

Volltext

634PPROGNOSTIC EVALUATION OF A MULTICENTER COHORT OF 484 PATIENTS WITH METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA von Vicente Conesa, M.A., Faez Garcia, L., Garrido, M., Custodio, A., López, C., Visa, L., Gallego Plazas, J., Fernandez Arrojo, S., Ramchandani, A., Murias, C., Iranzo, V., Múgica, M., Giraldo, C., Hindi, N., Erpel, F., Pineda, E., Buxo, E., Jofré, E., Jimenez Fonseca, P., Carmona-Bayonas, A.

Volltext